TWI912388B - Ｇｌｐ-１ｒ促效劑的晶型及其用途 - Google Patents
Ｇｌｐ-１ｒ促效劑的晶型及其用途Info
- Publication number
- TWI912388B TWI912388B TW110138006A TW110138006A TWI912388B TW I912388 B TWI912388 B TW I912388B TW 110138006 A TW110138006 A TW 110138006A TW 110138006 A TW110138006 A TW 110138006A TW I912388 B TWI912388 B TW I912388B
- Authority
- TW
- Taiwan
- Prior art keywords
- crystal form
- disease
- compound
- ray powder
- powder diffraction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020120814 | 2020-10-14 | ||
| WOPCT/CN2020/120814 | 2020-10-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202227421A TW202227421A (zh) | 2022-07-16 |
| TWI912388B true TWI912388B (zh) | 2026-01-21 |
Family
ID=78401981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110138006A TWI912388B (zh) | 2020-10-14 | 2021-10-13 | Ｇｌｐ-１ｒ促效劑的晶型及其用途 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12516041B2 (https=) |
| EP (1) | EP4228753B1 (https=) |
| JP (1) | JP7769695B2 (https=) |
| CN (1) | CN116710446B (https=) |
| AU (1) | AU2021359493A1 (https=) |
| CA (1) | CA3195264A1 (https=) |
| ES (1) | ES3041328T3 (https=) |
| TW (1) | TWI912388B (https=) |
| WO (1) | WO2022078352A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210069000A (ko) * | 2019-12-02 | 2021-06-10 | 현대약품 주식회사 | Glp-1 수용체 작용제 |
| KR20240068737A (ko) | 2021-09-27 | 2024-05-17 | 테른스 파마슈티칼스, 인크. | Glp-1r 효능제로서의 벤즈이미다졸 카복실산 |
| AU2022375634A1 (en) | 2021-10-25 | 2024-06-06 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| KR20240150488A (ko) | 2022-02-23 | 2024-10-15 | 테른스 파마슈티칼스, 인크. | Glp-1r 작용제로서의 화합물 |
| CN117362282B (zh) * | 2022-07-07 | 2026-04-21 | 杭州德睿智药科技有限公司 | Glp-1r激动剂的盐及其制备方法和应用 |
| AU2023310481A1 (en) * | 2022-07-18 | 2025-03-06 | Mindrank Therapeutics (Suzhou) New Drug Research And Development Co., Ltd | Polymorphic form of glp-1r agonist, preparation method therefor and use thereof |
| US20240398794A1 (en) | 2023-04-07 | 2024-12-05 | Terns Pharmaceuticals, Inc. | COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF |
| TW202521533A (zh) | 2023-09-14 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| US12291530B1 (en) | 2023-11-24 | 2025-05-06 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018109607A1 (en) * | 2016-12-16 | 2018-06-21 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| WO2020103815A1 (en) * | 2018-11-22 | 2020-05-28 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US7727983B2 (en) | 2008-03-07 | 2010-06-01 | Transtech Pharma, Inc. | Oxadiazoanthracene compounds for the treatment of diabetes |
| AR083878A1 (es) * | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| ES2943510T3 (es) * | 2018-06-15 | 2023-06-13 | Pfizer | Agonistas del receptor GLP-1 y usos del mismo |
| US10954221B2 (en) * | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| AU2020256647B2 (en) * | 2019-04-12 | 2025-07-31 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
-
2021
- 2021-10-13 TW TW110138006A patent/TWI912388B/zh active
- 2021-10-13 CA CA3195264A patent/CA3195264A1/en active Pending
- 2021-10-13 WO PCT/CN2021/123387 patent/WO2022078352A1/en not_active Ceased
- 2021-10-13 CN CN202180082321.9A patent/CN116710446B/zh active Active
- 2021-10-13 ES ES21798552T patent/ES3041328T3/es active Active
- 2021-10-13 AU AU2021359493A patent/AU2021359493A1/en active Pending
- 2021-10-13 JP JP2023523059A patent/JP7769695B2/ja active Active
- 2021-10-13 EP EP21798552.2A patent/EP4228753B1/en active Active
- 2021-10-13 US US18/031,380 patent/US12516041B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018109607A1 (en) * | 2016-12-16 | 2018-06-21 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| WO2020103815A1 (en) * | 2018-11-22 | 2020-05-28 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4228753C0 (en) | 2025-07-30 |
| JP2023546125A (ja) | 2023-11-01 |
| ES3041328T3 (en) | 2025-11-11 |
| EP4228753B1 (en) | 2025-07-30 |
| US12516041B2 (en) | 2026-01-06 |
| WO2022078352A1 (en) | 2022-04-21 |
| CA3195264A1 (en) | 2022-04-21 |
| AU2021359493A9 (en) | 2025-01-09 |
| US20230382899A1 (en) | 2023-11-30 |
| CN116710446A (zh) | 2023-09-05 |
| JP7769695B2 (ja) | 2025-11-13 |
| CN116710446B (zh) | 2024-10-18 |
| AU2021359493A1 (en) | 2023-06-15 |
| TW202227421A (zh) | 2022-07-16 |
| EP4228753A1 (en) | 2023-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI912388B (zh) | Ｇｌｐ-１ｒ促效劑的晶型及其用途 | |
| CN115867546B (zh) | Glp-1r激动剂的盐和晶形及其用途 | |
| TWI716458B (zh) | γ-羥基丁酸的前藥及其組合物和用途 | |
| KR20150028971A (ko) | 항바이러스성 화합물의 고체 형태 | |
| WO2010099698A1 (zh) | 四氢咪唑并[1,5-a]吡嗪衍生物的盐，其制备方法及其在医药上的应用 | |
| JP6657294B2 (ja) | ニューロトロフィン模倣化合物およびこれらの塩の結晶形態 | |
| HK1216530A1 (zh) | 神經營養因子模擬化合物及其鹽的結晶形式 | |
| TWI913272B (zh) | Ｇｌｐ-１ｒ促效劑之鹽和晶型及其用途 | |
| WO2019114693A1 (zh) | 达比加群酯衍生物及其药学用途 | |
| HK40089377B (en) | Crystal forms of glp-1r agonists and uses thereof | |
| HK40089377A (en) | Crystal forms of glp-1r agonists and uses thereof | |
| HK40087545A (en) | Salt and crystal forms of glp-1r agonists and uses thereof | |
| HK40087545B (en) | Salt and crystal forms of glp-1r agonists and uses thereof | |
| HK40107199A (zh) | 线粒体靶向肽 | |
| CN120230121A (zh) | 苯并噁嗪噁唑烷酮类化合物otb-658的晶型i及其制备方法和其组合物与用途 | |
| HK40102944A (zh) | 2-[(4-{6-[(4-氰基-2-氟苄基)氧基]吡啶-2-基}哌啶-1-基)甲基]-1-[(2s)-氧杂环丁烷-2-基甲基]-1h-苯并咪唑-6-羧酸，1，3-二羟基-2-(羟甲基)丙-2-胺盐的固体形式 | |
| HK1212970B (en) | Crystalline forms of neurotrophin mimetic compounds and their salts | |
| HK1177152B (en) | Crystalline forms of neurotrophin mimetic compounds and their salts | |
| HK1177152A1 (en) | Crystalline forms of neurotrophin mimetic compounds and their salts |